Ascent Group’s West Pharmaceutical WST Stock Holding History

Ascent Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-754	Closed	-$208K	–	802
2025 Q4	$208K	Buy	+754	New	+$206K	0.01%	712

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ascent Group's WST Position: Q1 2026 in Review

Ascent Group sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 754 shares — an estimated $208K sold.

Ascent Group first reported a position in WST in Q4 2025 and held it in 1 quarter. The position peaked at $208K in Q4 2025. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Ascent Group reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Ascent Group sold 754 West Pharmaceutical shares in Q1 2026, an estimated $208K.
Ascent Group first reported a position in West Pharmaceutical in Q4 2025 and held it in 1 quarter.
Ascent Group's West Pharmaceutical position peaked at $208K in Q4 2025.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.